 This is a phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high HA-high subjects with relapsedrefractory Non-Small Cell Lung Cancer NSCLC and HA-high subjects with relapsedrefractory gastric adenocarcinoma. 